Our finding should be validated in independent patient cohorts with a higher number of patients and in combination with IDH, TERT, and ATRX assessments to classify oligodendrogliomas according to WHO 2016 criteria combined with the analyses of telomerase versus alternative length of telomeres (ALT) activity for the maintenance of telomere length. This evidence concerns the gene ATRX and oligodendroglioma.